

## FORM 8-K

## CURRENT REPORT

Pursuant to Section 13 OR 15 (d) of the  
Securities Exchange Act of 1934

September 19, 2006

Date of Report (Date of earliest event reported)

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.  
(Exact Name of Registrant as specified in its Charter)

Delaware	333-92383	06-1397316
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

251 Ballardvale Street  
Wilmington, Massachusetts 01887  
(Address of Principal Executive Offices) (Zip Code)

978-658-6000  
(Registrant's Telephone Number, including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- |\_ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- |\_ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- |\_ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- |\_ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 2.02. Results of Operations and Financial Condition

The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific

## Edgar Filing: CHARLES RIVER LABORATORIES INTERNATIONAL INC - Form 8-K

reference in such a filing.

On September 19, 2006, Charles River Laboratories International, Inc. issued information on its Web site at <http://ir.criver.com> under "Financial Reconciliations" that contains financial results for the quarters ended March 26, 2005, June 26, 2005, and September 24, 2005 and for the quarter and fiscal year ended December 31, 2005, that have been reclassified to reflect the Company's sale of its Clinical Phase II-IV business and decision to close its Interventional and Surgical Services business in the second quarter of 2006, which are now reported as discontinued operations.

### ITEM 9.01. Financial Statements and Exhibits

(a) Not applicable.

(b) Not applicable.

(c) Exhibits.

99.1 Financial Results of Charles River Laboratories International, Inc. for the quarters ended March 26, 2005, June 26, 2005, and September 24, 2005 and for the quarter and fiscal year ended December 31, 2005.

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, we have duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHARLES RIVER LABORATORIES  
INTERNATIONAL, INC.

Dated: September 19, 2006

By: /s/ Joanne P. Acford

-----  
Joanne P. Acford, Corporate Senior Vice  
President, General Counsel and  
Corporate Secretary

### Exhibit Index

Exhibit No. -----	Description -----
99.1	Financial Results of Charles River Laboratories International, Inc. for the quarters ended March 26, 2005, June 26, 2005, and September 24, 2005 and for the quarter and fiscal year ended December 31, 2005.